Menu Icon
Menu Close Icon

everything is political

Open Search
EVENTS
Global Stage Events
Join us for more Global Stage events
ABOUT GZERO MEDIA
Blue Circle
Search
AI-powered search, human-powered content.
scroll to top arrow or icon

{{ subpage.title }}

Pens for the diabetes drug Ozempic sit on a production line to be packaged at the Danish drugmaker Novo Nordisk's site in Hillerod, Denmark.

REUTERS/Tom Little

How Ozempic is funding an AI supercomputer

The Danish company Novo Nordisk has gotten rich off of the success of Ozempic and Wegovy — two variants of the revolutionary drug called semaglutide that’s used for diabetes and weight loss respectively under different brand names. Since 2020, the company’s stock price has quadrupled. One of the biggest beneficiaries has been the Novo Nordisk Foundation, the pharmaceutical giant’s charitable arm and its largest shareholder.

Read moreShow less
novo nordisk foundationaiartificial intelligenceozempic

Subscribe to our free newsletter, GZERO Daily

Most Popular Videos

What Russia and North Korea gain from defense treaty

Trump, Putin, and Xi want to have more babies

Global leaders scramble to align with Trump

Latest

Trump’s immigration plan faces hurdles

US vetoes Gaza ceasefire resolution

How world leaders are preparing for Trump’s return

GZERO’s Dish of Delights, Nov. 19, 2024

Ukraine fires US missiles into Russia. What's next?

UN will resume aid flights to Haiti as gangs gain ground

Putin loosens the muzzle on Russia's nuclear weapons